# A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

> **NCT01858389** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 41 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Dacomitinib
- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT01858389
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01858389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01858389, "A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01858389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*